A medication name is not a complete evidence trail. For someone considering Mondae, the important questions extend beyond whether semaglutide and tirzepatide have been studied: Which preparation would be prescribed, who would dispense it, what monitoring would accompany it, and what would the patient actually pay? Mondae’s public documentation describes a real service model—online evaluation, prescribing when appropriate, outside pharmacy dispensing and home delivery—but does not establish clinical outcomes for that service or its compounded preparations.
This review examines Mondae’s public documentation consulted October 19, 2026, separating commercial promises, contractual responsibilities and clinical evidence. The distinction matters because several pages do not line up cleanly: homepage prices differ from product-page amounts, a continuing membership underpins a price promise despite advertising no membership fees, and a no-charge-before-approval statement sits beside nonrefundable consultation terms. These are unresolved documentary questions, not proof of improper conduct. They are also questions worth settling before authorizing payment.
At a glance
- Platform and clinical responsibility
- Mondae LLC operates the website; its terms assign medical services to contracted physicians and identify Bask Telehealth LLC in the care arrangement.Sources: [12]
- Compounded GLP-1 prices
- The homepage advertises compounded semaglutide from $69/month and compounded tirzepatide from $114/month; product pages display $87/month and $126/month, respectively, without clearly connecting those amounts to a plan length.
- Payment model
- Mondae and its providers describe services as cash-pay, do not accept commercial insurance and do not participate in Medicare or Medicaid.Sources: [12]
- Approval and consultation charges
- The FAQ says patients are not charged until physician approval, while the refund policy says consultation fees are nonrefundable even when medication is not prescribed.
Start with the product, not the ingredient’s reputation
Mondae advertises compounded semaglutide and compounded tirzepatide, with prescriptions required and treatment contingent on a licensed provider finding it medically appropriate. The public documentation reviewed does not establish the exact presentation, concentration, quantity supplied per shipment or specific anatomical administration route. Those details matter when evaluating what is actually being offered. An ingredient name alone cannot identify the finished preparation, its instructions or its relationship to research on a particular studied product.
Mondae’s disclosure correctly distinguishes compounded medication from FDA-approved products: compounded preparations do not undergo FDA premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence, nor does it validate a provider. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our guide to approved medicines and compounded preparations explains why these are separate evidence questions. The reviewed documentation does not establish which dispensing pharmacy would supply an individual patient.
Clinical studies are not Mondae outcome reports
The major semaglutide and tirzepatide trials provide relevant background, but they cannot supply missing evidence about Mondae. STEP 1 studied a specified subcutaneous semaglutide regimen over 68 weeks in adults without diabetes; SURMOUNT-1 studied specified subcutaneous tirzepatide regimens over 72 weeks, also excluding diabetes. Neither was a trial of Mondae or its compounded products. Their findings cannot establish this platform’s results, the performance of a preparation with undocumented details, or the outcome a particular patient should expect.
This distinction also prevents a misleading comparison between brands or providers based on separate trial averages. Different trials are not a randomized head-to-head comparison, and an ingredient’s research history is not a service-quality measure. Our explanation of why a clinical trial is not a telehealth company performance report provides a framework for reading such claims. For Mondae, the useful next evidence would be identifiable product information, a documented monitoring process and appropriately described service-specific outcomes—not simply another reference to familiar medication research.
Who evaluates, prescribes and stays involved
Mondae LLC owns and operates the website, but its terms say Mondae does not provide medical services. Those services are assigned to a contracted network of physicians described as licensed in the patient’s state. The terms also identify Bask Telehealth LLC as part of the telehealth arrangement and give its mailing address as 555 Madison Ave., Suite 1202, New York, NY 10022. These disclosures identify organizational roles; they do not independently verify the license or identity of the professional assigned to a particular patient.
The advertised process begins with a secure questionnaire covering medical history, current medications and treatment goals. A U.S.-licensed healthcare provider then reviews the information and conducts a consultation to determine appropriateness. During treatment, Mondae advertises secure portal messaging for questions, dosage concerns and requests for follow-up consultations or clinically appropriate adjustments. That is more informative than a bare prescription offer, but the reviewed documentation does not establish scheduled follow-up frequency, response deadlines or mandatory testing. NIDDK describes follow-up as an assessment of tolerance and response, not merely continued access to medication.
The advertised prices need a plan-specific explanation
Mondae publishes concrete prices, but not a clear explanation of why its homepage and product pages differ. The compounded GLP-1 pages show one-, three- and six-month options; the other three product pages show one- and three-month options. The displayed monthly amounts are not unambiguously tied to an option in the reviewed documentation. Consequently, neither the lowest homepage price nor the product-page amount can be treated as a verified quote for a particular enrollment. Plan duration also does not establish medication quantity, minimum commitment or mandatory prepayment.
The broader catalog includes sermorelin injection, NAD+ injection and glutathione injection, each advertised from $95 with monthly billing on the homepage and at $99 per month on its product page. Those listings establish offerings, not clinical benefits. Across the product pages, Mondae advertises no membership fees, one-to-one provider guidance and the same price at every dose. The record does not confirm whether consultation fees, laboratory work, administration supplies or shipping are included. A useful written quote would identify the selected product, plan, first charge, later charges and any separately billed services.
| Offering | Homepage advertisement | Product-page display |
|---|---|---|
| Compounded semaglutide | From $69/month | $87/month; 1-, 3-, 6-month options |
| Compounded tirzepatide | From $114/month | $126/month; 1-, 3-, 6-month options |
| Sermorelin injection | From $95; billed monthly | $99/month; 1-, 3-month options |
| NAD+ injection | From $95; billed monthly | $99/month; 1-, 3-month options |
| Glutathione injection | From $95; billed monthly | $99/month; 1-, 3-month options |
Price continuity is clearer than the membership mechanics
Mondae says a patient’s monthly price does not rise when the dose changes under provider guidance. Its more expansive promise that the starting price is kept “for life” is conditional: the membership must remain active. That condition belongs alongside the promise, not in fine print beneath an assumed permanent rate. Advertising no membership fees does not necessarily contradict having a membership, but the public documentation does not adequately explain what maintains active status, what interruption does to pricing or how membership termination works.
The payment model itself is explicit. Mondae and its providers do not accept commercial health insurance, are not in-network with commercial plans and are not enrolled in Medicare or Medicaid; patients choose cash-pay services outside those programs. The record does not settle automatic-renewal terms, future-charge cancellation deadlines or whether longer plans involve upfront collection. The reviewed terms also had a central portion unavailable, limiting a complete assessment of payment and termination provisions. These gaps make written confirmation of the billing schedule more useful than assuming that a monthly price means monthly collection.
Approval, cancellation and refunds describe different events
The homepage FAQ says patients will not be charged until a physician approves treatment. The refund policy separately says telehealth consultation fees are nonrefundable, including when no medication is prescribed. The documentation does not explain how these statements operate together or identify a consultation fee amount. A prospective patient should ask which charge is authorized before evaluation, what happens after a declined prescription and whether the no-charge statement applies to every component. It would be inaccurate to resolve this tension by promising that an unsuccessful evaluation is always free.
Cancellation is allowed only before medication has been dispensed or shipped; dispensing alone can therefore close the cancellation window. For a successfully canceled order before shipping, the policy says a full refund is issued within five to seven business days. Other refund requests are not guaranteed: review takes five to seven business days, and approved refunds are issued to the original payment method within ten to fourteen business days. These are distinct policy pathways, not one universal timetable, and issuance does not guarantee bank receipt. Requests require an order number, purchase date, explanation and potentially supporting documentation.
Pharmacy and delivery claims stop short of a complete chain
Mondae says state-licensed U.S. clinicians prescribe medication and licensed U.S. pharmacies dispense it; Mondae itself says it does not manufacture medication. The reviewed documentation does not name the dispensing pharmacies, establish which entity compounds a particular preparation or permit independent licensing verification. If prescribed, medication is advertised as delivered directly to the patient with tracking. “Quickly” and “discreetly” are provider descriptions, not quantified dispatch or arrival commitments. The shipping-policy content was unavailable for review, leaving carrier, cold-chain arrangements, shipment frequency and transit timing unestablished.
The refund policy is more specific about delivery problems: damaged or defective medication must be reported by email within 48 hours of delivery, with photographs of the medication and original packaging. Confirmed problems generally receive a free replacement; a refund is available only if replacement is impossible. Confirmed incorrect orders receive the correct medication at no additional cost, with return instructions if needed. Separately, FDA advises not using an injectable GLP-1 product that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. Our guide to reading delivery and cold-chain claims explains the distinction between a shipping promise and documented handling.
Availability, support and privacy need separate checks
Mondae advertises availability in all 50 states, while its terms restrict use to people located in the United States and make eligibility depend on the state and service involved. That does not establish every treatment’s availability everywhere. The age provisions also need careful reading: terms generally specify age 18 or older, include a parental-consent exception and warn that some services may require being over 21. The privacy policy says under-18 accounts are not knowingly permitted. Together, these provisions do not confirm a pediatric treatment program or establish individual medical eligibility.
Purchase support is advertised from 8 a.m. to 8 p.m. Eastern Time, without specified days in that passage. Policies direct several requests to email, but the reviewed copies did not expose a usable address. Clinical questions have an advertised portal route; ordinary email and text messages are described in the terms as unencrypted. The privacy policy also states that sensitive personal data may be sold, with consent where required. Before submitting health information, readers can use our provider-documentation checklist to distinguish identifiable contact routes, stated privacy practices and independently verified protections.
Questions & answers
Does Mondae offer FDA-approved semaglutide or tirzepatide?
The documented offerings reviewed here are compounded semaglutide and compounded tirzepatide. References to approved brands in disclosures do not establish that Mondae offers those brands. Mondae acknowledges that compounded medications are not FDA approved. Ask for the exact prescribed product and dispensing pharmacy rather than assuming an ingredient name identifies an approved finished medication.
What should I expect to pay for Mondae’s GLP-1 program?
Published amounts differ: the homepage advertises compounded semaglutide from $69 per month and compounded tirzepatide from $114 per month, while product pages show $87 and $126 per month. The documentation does not clearly tie those displays to particular plan lengths or establish all included services. Request an itemized quote showing the first payment, collection interval, renewal amount and any consultation, testing, supply or delivery charges.
Will Mondae charge me if treatment is not approved?
The public statements do not resolve that question completely. The FAQ says no charge occurs until physician approval, but the refund policy makes consultation fees nonrefundable even without a prescription. Before evaluation, ask whether any consultation charge applies if treatment is declined, how much it is and how that condition fits the approval-based charging promise. Do not assume either statement silently cancels the other.
Can I use insurance, Medicare or Medicaid with Mondae?
Mondae’s terms describe a cash-pay model. Mondae and its providers do not accept commercial insurance, are not in-network with commercial plans and are not enrolled in Medicare or Medicaid. This is a statement about the service’s payment arrangement, not a determination of your plan’s coverage elsewhere. The documentation reviewed does not establish reimbursement eligibility for an individual patient.
How do I reach a clinician during treatment?
Mondae advertises secure messaging through the online patient portal for questions, dosage concerns and requests for follow-up or medically appropriate adjustments. The documentation does not specify a guaranteed clinical response time or scheduled visit frequency. Purchase-support hours are a separate disclosure, not a promise of clinician availability. Ask who monitors clinical messages, when replies are expected and whether additional consultations carry separate charges.
What happens if my medication arrives damaged or warm?
Mondae requires emailed reports of damage or defects within 48 hours of delivery, including photos of the medication and original packaging. Confirmed problems generally receive a no-cost replacement, with refunds only if replacement is impossible. Independently, FDA advises not using an injectable GLP-1 medication that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. Confirm a usable reporting address before shipment.
Our assessment
Mondae documents a recognizable telehealth pathway, conditional prescribing, portal communication and specific remedies for confirmed delivery errors. It also discloses compounded-product status and a cash-pay model. Those are useful foundations, but they do not establish clinical effectiveness for Mondae’s preparations or complete accountability across the prescribing and pharmacy chain. The most consequential unresolved issues are the unidentified dispensing pharmacies, missing formulation details, unexplained price differences, uncertain membership mechanics and conflicting implications of approval-based charging and nonrefundable consultations. A reasonable documentary next step is to obtain a product-specific, itemized explanation covering pharmacy identity, clinical follow-up, first and subsequent charges, and cancellation responsibilities. Mondae’s public record supports further inquiry—not a safety endorsement, a promised outcome or an assumption that the lowest advertised price describes the full service.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Mondae — policies/refunds ↗
- Mondae — official website ↗
- Mondae — treatments/compounded tirzepatide ↗
- Mondae — treatments/glutathione ↗
- Mondae — treatments/nad ↗
- Mondae — policies/privacy policy ↗
- Mondae — treatments/compounded semaglutide ↗
- Mondae — policies/terms of service ↗
- Mondae — treatments/sermorelin ↗